Education about Non-Alcoholic Steatohepatitis (NASH) and the Role of PPAR Agonists
Clinical Chemistry In NAFLD Part 3 – Biomarkers and Hepatic Fibrosis
Discover the intricate dynamics of Clinical Chemistry in NAFLD with Dr. Guillaume Grzych, a leading
Clinical Chemistry in NAFLD Part 2 – Biomarkers, Hepatic Steatosis and NASH
Discover how key biomarkers like Fatty Liver Index and SteatoTest are transforming NAFLD diagnosis and
Clinical Chemistry in NAFLD Part 1 – Interest and Why?
Explore the complexities of NAFLD (Non-Alcoholic Fatty Liver Disease), now also known as MAFLD, and
Updates in ADA’s 2023 Standard of Care in Diabetes
Explore ADA’s 2023 updates on diabetes care, focusing on non-alcoholic fatty liver disease (NAFLD) and
Discover all about NASH, NAFLD PPAR agonists ⟶
Link Between NAFLD and Heart Failure – A Cardiology Perspective Slide
Join Dr Marat Fudim in this webinar as he delves into the complex interplay between non-alcoholic fatty liver disease (NAFLD)
Multistakeholder Approach to Innovations in NAFLD Care Slides
Explore with the slides the significance of a multistakeholder approach in NAFLD care as it tackles the complexities of comorbidities,
NAFLD Pathophysiologic Role of Intrahepatic Vasculature Slides
Dr. Kwanten (Belgium) discusses the role of pathophysiological role of intrahepatic vasculature in non-alcoholic fatty liver disease (NAFLD). He mentions
Exploring the Promise of Pan-PPAR Agonism
Peroxisome proliferated-activated receptors (PPARs), including α, β/δ and γ isotypes, are a nuclear receptor family of lipid sensors activated by natural fatty acid derivatives and pharmacological agonists.
Advancing Fibrosis Imaging: An Evaluation of Radiotracer Efficacy
Tissue fibrosis is induced by an excessive collagen deposition in organs suffering from inflammation and is associated with several diseases, including non-alcoholic steatohepatitis (NASH).
Geographical burden of NAFLD: a review
Over the past few decades, non-alcoholic fatty liver disease (NAFLD) has become a growing problem, alongside the increasing rates of obesity and type 2 diabetes.
Global research on fatty liver disease: a review
In this study, a large, global, multidisciplinary panel discussed priorities within the field of fatty liver disease, including its burden, policies surrounding the issue and treatment options.
New this week!
Clinical Chemistry In NAFLD Part 3 – Biomarkers and Hepatic Fibrosis
Discover the intricate dynamics of Clinical Chemistry in NAFLD with Dr. Guillaume Grzych, a leading expert in medical biology and advanced computational techniques. Dive deep into the pathophysiology
EDITOR OF THE MONTH!
Dr. Guillaume Grzych is a Medical Biologist with a specialization in biochemistry, currently serving at the University Hospital of Lille. He holds the position of Associate Professor and Hospital Practitioner, with dual qualifications in Pharmacy (PharmD) and Medicine (PhD).
Latest Research toward the treatment of NASH disease
Knowledge is crucial for healthcare professionals to manage and diagnose patients with NASH and NAFLD. Over the years, we have been increasingly communicating the results achieved by research, showcasing the latest on therapy to diagnosis and management.
LATEST SCIENTIFIC ADVANCES IN NASH, NAFLD & PPAR AGONISTS
Key Messages from 2 Recent Studies on NAFLD Severity in People with Type 2 Diabetes
Unveiling the high prevalence of NAFLD and advanced fibrosis in type 2 diabetes patients –
Building a Better Future For Patients with NAFLD and NASH
On International NASH Day 2023, join Michael Betel of the Fatty Liver Alliance as he
Link Between NAFLD and Heart Failure – A Cardiology Perspective
Join Dr Marat Fudim in this webinar as he delves into the complex interplay between
Multistakeholder Approach to Innovations in NAFLD Care
Discover the importance of a multistakeholder approach in NAFLD care, addressing the challenges of comorbidities,
The Odyssey for an Optimal NASH Biomarker: Challenges and Opportunities in 2023
Explore the challenges and opportunities in the quest for a non-invasive diagnosis tool of non-alcoholic
NAFLD Pathophysiologic Role of Intrahepatic Vasculature
Dr. Kwanten (Belgium) discusses the pathophysiological role of intrahepatic vasculature in non-alcoholic fatty liver disease
Non-Invasive Assessment of cACLD and Portal Hypertension
Dr. Jörn Schattenberg (Germany) analyses the latest on the assessment in cirrhosis along with his
Fibrosis vs. steatohepatitis in NASH: key prognostic and regulatory implications
Fibrosis is an independent predictor of liver-related mortality but rarely if ever occurs without NASH
Burden of Liver-Related Comorbidities in Cardiovascular Disease
In this video Prof. Sven Francque explores that NAFLD is prevalent in patients with cardiovascular
How to Integrate NASH Assessment and Management Into the Care of Diabetic Patient
Dr. Laurent Castera (France) discusses how healthcare professionals can integrate non-alcoholic steatohepatitis (NASH) assessment and
HCC Pathogenesis in NASH and the Impact of Fibrosis
Dr. Scott Friedman talks about HCC pathogenesis in NASH and the impact of fibrosis. This
Natural history & clinical outcomes in adults with NAFLD
Dr. Kris Kowdley explains the natural history and clinical outcomes in adults with non -alcoholic
Webinar & Replay
Exploring the Promise of Pan-PPAR Agonism
Advancing Fibrosis Imaging: An Evaluation of Radiotracer Efficacy
Geographical burden of NAFLD: a review
Global research on fatty liver disease: a review
Managing Hepatocellular Carcinoma in NAFLD: a review
The new paradigm of cardiometabolic syndrome: a review
CATEGORIES
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES
Latest articles from PubMed
- The effects of zinc supplementation on the metabolic factors in patients with non-alcoholic fatty liver disease: a randomized, double-blinded, placebo-controlled clinical trial November 28, 2023
- Effect of triggering receptor expressed on myeloid cells 2-associated alterations on lipid metabolism in macrophages in the development of non-alcoholic fatty liver disease November 27, 2023
- From complement to complosome in non-alcoholic fatty liver disease: When location matters November 27, 2023
- Thrombospondin 2 is a key determinant of fibrogenesis in non-alcoholic fatty liver disease November 27, 2023
- Low Muscle Strength as Risk Factor for Non-Alcoholic Fatty Liver Disease in Different Metabolic Conditions November 27, 2023
- Association between chronotype and metabolic-associated fatty liver disease in employed adults: A longitudinal study in Southwestern China November 27, 2023
- Protective Effect of Sea Buckthorn (Hipphophae Rhamnoides) Extract on Liver Injury Induced by High-Fat Diet in Mice November 26, 2023
- Application of artificial intelligence techniques for non-alcoholic fatty liver disease diagnosis: A systematic review (2005-2023) November 26, 2023
The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system, thus improving the lives of millions of patients worldwide.